Description
InformationRadotinib Radotinib (IY-5511) is a selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM, used to treat Chronic Myeloid Leukemia.TargetsBCR-ABL1 34 nMIn vitroRadotinib binds BCR-ABL1 and reduces phosphorylation of CrkL, a BCR-ABL1 target protein. Radotinib also effectively inhibits the proliferation of common mutant clones of BCR-ABL1, with the exception of T315I. In AML cells, radotinib significantly decreases the cell viability, promotes differentiation, and induces CD11b expression and apoptosis. In NB4, THP-1, and Kasumi-1 cells, radotinib also induces CD11b expression, and decreases the viability.Cell Research(from reference)Cell lines：BMCs of AML and CML patients, NB4, HL60, KASUMI-1, and THP-1 cells Concentrations：~100 µM Incubation Time：72 h